Mechanisms of Prostaglandin E2 Release by Intact Cells Expressing Cyclooxygenase-2: Evidence for a ‘Two-Component’ Model1

  1. Michael A. Saunders2,
  2. Maria G. Belvisi2,3,
  3. Guiseppe Cirino4,
  4. P. J. Barnes2,
  5. Timothy D. Warner5 and
  6. Jane A. Mitchell6
  1. Unit of Critical Care Medicine, Royal Brompton Hospital, Imperial College School of Medicine, National Heart and Lung Institute, London, England
     
    Next Section

    Abstract

    Prostaglandin (PG) release in cells expressing constitutive cyclooxygenase-1 is known to be regulated by liberation of arachidonic acid by phospholipase A2 followed by metabolism by cyclooxygenase. However, the relative contribution of phospholipase A2 to the release of PGs in cells expressing cyclooxygenase-2 is not clear. We addressed this question by using radioimmunoassay to measure PGE2 release by human cells (A549) induced to express cyclooxygenase-2 (measured by Western blot analysis) by interleukin-1β. Cells were either unstimulated or stimulated with agents known to activate phospholipase A2(bradykinin, Des-Arg10-kallidin, or the calcium ionophore A23187) or treated with exogenous arachidonic acid. When cells were treated to express cyclooxygenase-2, the levels of PGE2released over 15 min were undetectable; however, in the same cells stimulated with bradykinin, A23187, or arachidonic acid, large amounts of prostanoid were produced. Using selective inhibitors/antagonists, we found that the effects of bradykinin were mediated by B2 receptor activation and that prostanoid release was due to cyclooxygenase-2, and not cyclooxygenase-1, activity. In addition, we show that the release of PGE2 stimulated by either bradykinin, A23187, or arachidonic acid was inhibited by the phospholipase A2 inhibitor arachidonate trifluoromethyl ketone. Hence, we have demonstrated that PGE2 is released by two components: induction of cyclooxygenase-2 and supply of substrate, probably via activation of phospholipase A2. This is illustrated in A549 cells by a clear synergy between the cytokine interleukin-1β and the kinin bradykinin.

    Prostaglandins (PGs) and thromboxanes are potent modulators of biological function, particularly inflammation. They are produced via a complex enzyme cascade regulated by two principal enzymes: phospholipase A2 (PLA2) and cyclooxygenase (COX). PLA2 mobilizes arachidonic acid from cellular phospholipids, which is then metabolized by COX to PGH2 (Hamberg et al., 1974), the common substrate for a number of synthetase and isomerases essential to the formation of a variety of prostanoids.

    PLA2 exists in both calcium-dependent and -independent isoforms. The extracellular, or secretory, PLA2 (sPLA2) requires millimolar levels of calcium for activation, whereas the intracellular, or cytosolic, PLA2 (cPLA2) requires only nanomolar levels of calcium (for a review, see Mukherjee et al., 1994). Thus, sPLA2 is activated continuously by the levels of calcium found in the extracellular environment, whereas cPLA2 is activated via increases in intracellular calcium elicited by inflammatory mediators such as bradykinin (Burch and Axelrod, 1987; Slivka and Insel, 1988;Ricupero et al., 1993).

    Similar to PLA2, COX exists in multiple isoforms. A constitutive isoform (COX-1) is thought to be responsible for the “housekeeping” functions of the enzyme, whereas the inducible (COX-2) isoform (Xie et al., 1991; Mitchell et al., 1995) is thought to mediate inflammatory events. COX-2 is expressed in vitro in response to a number of proinflammatory mediators, including interleukin (IL)-1β (Lee et al., 1992; Hempel et al., 1994; Mitchell et al., 1994; Newman et al., 1994; Croxtall et al., 1996; Newton et al., 1996; Vadas et al., 1996; Belvisi et al., 1997), and in vivo at the site of inflammation (Vane et al., 1994; Chan et al., 1995).

    Inflammation is orchestrated by mediators that are released in tissues in chronological order. For instance, the formations of amines (e.g., histamine) and kinins (e.g., bradykinin) often are early events that are followed by a later phase involving the infiltration of activated leukocytes and the release of cytokines (e.g., IL-1β). In chronic inflammatory diseases such as rheumatoid arthritis or asthma, early- and late-phase inflammatory mediators may be released in synchronized cycles. Thus, activation of PLA2 (e.g., with bradykinin) and expression of COX-2 (e.g., by IL-1β) may occur simultaneously at the same site of inflammation. Therefore, to further understand how PLA2 and COX-2 interact to produce prostanoids during inflammatory events, we investigated the effect of stimulating endogenous arachidonic acid release with bradykinin or A23187 or of directly supplying exogenous substrate on PGE2 release from the human pulmonary cell line A549 induced with IL-1β to express COX-2 (Mitchell et al., 1994,1997). We addressed the roles of cPLA2 and sPLA2 in these responses by using “specific” inhibitors of these enzymes. Furthermore, we used the B1 agonist Des-Arg10-kallidin and the B2 antagonist Hoe140 to establish which bradykinin receptor is responsible for prostanoid release in these cells.

    Previous SectionNext Section

    Materials and Methods

    Culture of Human Pulmonary Cell Line A549.

    The human pulmonary cell line A549 (Giard et al.,1973) was purchased from American Type Culture Collection (Rockville, MD). Cells were cultured onto either 6- or 96-well plates in Dulbecco’s modified Eagle’s medium containing 2 mM calcium (unless otherwise stated) supplemented with 10% fetal calf serum, 2 mM l-glutamine, 100 μg/ml streptomycin, 100 units/ml penicillin, and 2.5 μg/ml amphotericin B, an antifungal agent. Cells were treated with IL-1β or, in some experiments, medium controls at confluence.

    Cell Treatments to Assess Release of PGE2 from A549 Exposed to Bradykinin, Des-Arg10-Kallidin, Arachidonic Acid, or Calcium Ionophore A23187.

    Cells were exposed to IL-1β (10 ng/ml) or medium for 24 h. Medium was then removed for analysis of PGE2 by radioimmunoassay (Mitchell et al., 1993, 1994), and fresh medium was added alone or containing either bradykinin (1 pM to 100 μM), the B1-specific agonist Des-Arg10-kallidin (1 pM to 100 μM), A23187 (100 nM to 300 μM), or arachidonic acid (100 nM to 300 μM). After 15 min, the medium was removed for analysis of PGE2. In subsequent experiments, cells were pretreated for 30 min (24 h after IL-1β) with either the B2 antagonist Hoe140 (Hock et al., 1991), the mixed COX-1/COX-2 inhibitor indomethacin (0.01–10 μM) (Meade et al., 1993; Mitchell et al., 1993), the COX-2-selective inhibitor L-745,337 (0.01–10 μM) (Chan et al., 1995), or the PLA2 inhibitors arachidonate trifluoromethyl ketone (AACOCF3), palmitoyl trifluoromethyl ketone (PACOCF3), aristolochic acid, or 12-ep-scalaradial. Cells then were stimulated for 15 min with equieffective concentrations of bradykinin (1 μM), A23187 (10 μM), and arachidonic acid (30 μM) for PGE2 release, measured by radioimmunoassay as above.

    Western Blot Analysis.

    Western blot analysis was performed as described previously (Mitchell et al., 1993,1994). Briefly, cells were grown to confluence on 6-well plates and were treated for 24 h with either vehicle or IL-1β (10 ng/ml). After 24 h, the medium was removed, and the cells were washed with Hanks’ balanced salt solution. The cells then were incubated with an extraction buffer [50 mM Tris, 10 mM ethylenediaminetetraacetic acid, 1% Triton X-100 (v/v), 1 mM phenylmethylsulfonyl fluoride, 50 μM pepstatin A, and 0.2 mM leupeptin]. The resulting cell extract was boiled with gel loading buffer [50 mM Tris, 10% sodium dodecyl sulfate (SDS), 10% glycerol, 10% 2-mercaptoethanol, and 2 mg/ml bromophenol blue] in a ratio of 1:1. Approximately 10 μg of protein, determined by Bradford protein assay, was loaded onto a 4% SDS stacking/7.5% SDS separating gel. After electrophoretic separation (1.5 h at 125–200 V), the samples were transferred to nitrocellulose (1 h at 0.3 A; Bio-Rad, Hercules, CA) and primed with a specific polyclonal antibody raised against murine COX-2 (Chan et al., 1995). The blot then was incubated with a secondary antibody linked to horseradish peroxidase and visualized using enhanced chemiluminescence (ECL; Amersham, Arlington Heights, IL).

    Cell Viability.

    At the end of each treatment, the cell viability was assessed by the mitochondrial-dependent reduction in 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide to formazan (Mitchell et al., 1994). None of the cell treatments outlined above had an effect on cell viability unless otherwise stated.

    Purified COX-2 Activity.

    As described previously (Mitchell et al., 1997), ovine purified COX-2 was obtained from Cayman Chemical Co. (Ann Arbor, MI). Pure COX-2 and the cofactors glutathione (5 mM), epinephrine (5 mM), and hematin (1 μM) were dissolved in 50 mM Tris buffer, pH 7.5. Hematin was first dissolved in a concentrated stock of 100 mM in 1 M NaOH before being further diluted in Tris buffer. Enzyme reactions were carried out in individual wells of 96-well plates with a final reaction volume of 200 μl. Different concentrations of the PLA2 inhibitors were added to the plate, followed by the addition of 10 units of enzyme (180 μl). The plates were incubated at 37°C for 30 min before arachidonic acid (30 μM) was added for an additional 15 min. The reaction was stopped by heating the plate to 100°C for 5 min. The 96-well plate was then centrifuged at 10,000g for 10 min, and appropriate samples were removed for the measurement of PGE2 by radioimmunoassay.

    Materials.

    Bradykinin, Des-Arg10-kallidin, and Hoe140 were purchased from Scientific Marketing Associates (Barnet, Hertfordshire, UK). IL-1β was purchased from Boehringer-Mannheim (Lewes, East Sussex, UK). COX-2 antibody and L-745,337 were a kind gift from Dr. Ian Rodger (Merck Frosst, Point du Claire, Quebec, Canada). The PLA2 inhibitors arachidonate trifluoromethyl ketone (AACOCF3), palmitoyl trifluoromethyl ketone (PACOCF3), aristolochic acid, and 12 epi-scalaradial were purchased from Calbiochem Novabiochem (San Diego, CA).

    Statistical Analysis.

    Results are shown as the mean ± S.E.M. from n determinations. Where appropriate, data were analyzed by Kruskal-Wallis nonparametric analysis of variance test followed by Dunn’s test for multiple comparisons. All treatments were compared with control values, and p < .05 was considered to be significant. Apparent pKbwas determined using the following equation: Apparent pKb = −log(dose ratio − 1) − log[antagonist].

    Previous SectionNext Section

    Results

    Effect of IL-1β on COX-2 Expression in A549 over 24 h.

    As we (Mitchell et al., 1994, 1997) and others (Newman et al., 1994;Croxtall et al., 1996; Newton et al., 1996) have previously shown, A549 released undetectable (<0.2 ng/ml) levels of PGE2 and expressed undetectable levels of COX-2 protein (Fig.1) when cultured under “control” culture conditions, measured after a 24-h period. However, when A549 cells were cultured in the presence of IL-1β (10 ng/ml), cells released 12.8 ± 1.5 ng/ml (n = 9) PGE2 in 24 h and expressed COX-2 protein (Fig. 1).

    Figure 1
    View larger version:
    Figure 1

    Representative Western blot analysis of extracts from A549 with a specific antibody raised against COX-2 that recognizes a band of approximately 70 kDa. Each lane was loaded with approximately 10 μg of protein. Left, untreated A549 after 24 h. Right, A549 treated with IL-1β for 24 h.

    Release of PGE2 by Cells Pretreated with IL-1β followed by Stimulation with Bradykinin, Des-Arg10-Kallidin, A23187, or Arachidonic Acid.

    In contrast to results obtained with COX-2-expressing cells incubated for 24 h (as above), A549 cells, pretreated with IL-1β for 24 h, released undetectable levels of PGE2 when exposed to medium alone for 15 min (Fig. 2). However, COX-2-expressing cells released PGE2 in a concentration-dependent manner when exposed to bradykinin (Fig. 2), A23187 (Fig. 3), or arachidonic acid (Fig.3) with Emaxvalues for 15 min in excess of those obtained with IL-1β alone for 24 h. The B1-selective agonist Des-Arg10-kallidin had no significant effect on PGE2 release from IL-1β-stimulated A549 cells (n = 9; Fig. 2). The release of PGE2elicited by bradykinin was inhibited by the B2 antagonist Hoe140 (1 μM), given 30 min before bradykinin treatment, with an apparent pKb of 7.8 ± 0.2. Arachidonic acid also elicited PGE2 release from IL-1β-treated cells in a concentration-dependent manner; although due to toxic effects, it was not possible to achieve a maximal response (Fig. 3b;n = 9). Bradykinin (Fig. 2), Des-Arg10-kallidin, A23187, or arachidonic acid did not release detectable PGE2 from A549 cultured without IL-1β.

    Figure 2
    View larger version:
    Figure 2

    Release of PGE2 from A549 cells pretreated with IL-1β (10 ng/ml) for 24 h followed by a 15-min exposure to bradykinin. A, synergistic relationship between IL-1β (10 ng/ml) and bradykinin (1 μM) for the release of PGE2 from A549 cells. Similar data were obtained when cells were stimulated with A23187 or arachidonic acid. B, concentration-dependent release of PGE2 by bradykinin in cells pretreated with IL-1β (▴). •, release of PGE2 by cells pretreated with IL-1β and stimulated with the B1-selective agonist Des-Arg10-kallidin. Data represent the mean ± S.E.M. for nine determinations performed on 3 experimental days.

    Figure 3
    View larger version:
    Figure 3

    Demonstrates the release of PGE2 from A549 cells pretreated with IL-1β (10 ng/ml) for 24 h followed by a 15-min exposure to (A) the calcium ionophore A23187 or (B) exogenous arachidonic acid for 15 min. Data represent the mean ± S.E.M. for six determinations performed on 3 experimental days.

    Effects of COX-2-Selective Inhibitor L-745,337 and COX-1/COX-2 Inhibitor Indomethacin on Bradykinin-, A23187-, or Arachidonic Acid-Stimulated PGE2 Release.

    In COX-2-expressing cells, the release of PGE2 stimulated by equieffective, for PGE2 release, concentrations of bradykinin (1 μM), A23187 (10 μM), and arachidonic acid (30 μM) was inhibited in a concentration-dependent manner by indomethacin with a similar potency for each agonist (Fig. 4; n = 6). Moreover, L-745,337 inhibited PGE2 release stimulated by bradykinin more potently than that stimulated by A23187 or arachidonic acid (Fig. 4;n = 6).

    Figure 4
    View larger version:
    Figure 4

    Inhibitory effects of indomethacin (A) or L-745,337 (B) on COX activity in IL-1β-primed A549 cells stimulated with bradykinin (BK; ■; 1 μM), A23187 (▪; 10 μM), or arachidonic acid (AA; •; 30 μM). COX was measured by the release of PGE2 and calculated as percentage release in the absence of COX inhibitor (control). Data represent the mean ± S.E.M. for six determinations carried out on 3 experimental days.

    Effects of AACOCF3 and Other PLA2Inhibitors on COX-2 in Intact Cells and in Purified Form.

    In separate experiments, the so-called cPLA2 inhibitor AACOCF3 (Bartoli et al., 1994) caused concentration-dependent inhibitions of PGE2 release by A549 cells, expressing COX-2, and stimulated with equieffective (for PGE2 release) concentrations of bradykinin (1 μM), A23187 (10 μM), or arachidonic acid (30 μM) (Fig. 5; n= 6). However, AACOCF3directly inhibited purified COX-2 activity at similar concentrations (Fig. 5; n = 4). By contrast, the inhibitors PACOCF3 (calcium-independent PLA2 inhibitor;Ackermann et al., 1995), aristolochic acid (inhibitor of snake venom, human platelet, and synovial fluid sPLA2 as well as cPLA2), and 12-epi-scalaradial (inhibitor of bee venom and neutrophil PLA2 as well as cPLA2) had no effect at concentrations up to 100 μM on COX-2 activity in whole cells stimulated with 1 μM bradykinin (control, 100%; plus 100 μM PACOCF3, 101 ± 15%; plus 100 μM 12-epi-scalaradial, 105 ± 10%; plus 100 μM aristolic acid, 68 ± 25%), 10 μM A23187 (control, 100%; plus 100 μM PACOCF3, 108 ± 1%; plus 100 μM 12-epi-scalaradial, 69 ± 28%; plus 100 μM aristolic acid, 95 ± 15%), or 30 μM arachidonic acid (control, 100%; plus 100 μM PACOCF3, 92 ± 6%; plus 100 μM 12-epi-scalaradial, 72 ± 19%; plus 100 μM aristolic acid, 74 ± 22%) (n = 4–6). In addition, at concentrations of 100 μM, no effect of PACOCF3 (102 ± 20%), 12-epi-scalaradial (75 ± 30%), or aristolic acid (81 ± 25%) was seen on PGE2 production by purified COX-2 (n = 4).

    Figure 5
    View larger version:
    Figure 5

    A, effect of the cytosolic phospholipase A2 inhibitor AACOCF3 on COX-2 activity in whole cells pretreated with IL-1β for 24 h before being stimulated for 15 min with either bradykinin (BK), arachidonic acid (AA), or A23187. B, effect of AACOCF3 on purified COX-2 activity measured in the presence of 30 μM arachidonic acid. Data represent the mean ± S.E.M. for six (A) or four (B) experiments.

    Previous SectionNext Section

    Discussion

    This study demonstrates that when COX-2 is induced in intact cells, a secondary inflammatory stimulus is required to achieve maximum prostanoid release. Thus, a “two-component” system is required for prostanoid release in cells expressing COX-2 (Fig. 6). However, we and others (Mitchell et al., 1995) have demonstrated, in a variety of cell types, that induction of COX-2 stimulates the release of PGE2 (usually measured over a 24-h period) without the need for a secondary agonist. Here, we confirm that after 24 h, IL-1β induces COX-2 and releases PGE2; however, this release proved to be very low, in fact undetectable, when measured over a 15-min period. This contrasts with the large amounts of PGE2 released when cells were treated with IL-1β followed with secondary stimuli such as bradykinin, A23187, or exogenous arachidonic acid. The “low” level of PGE2 release by cells stimulated with IL-1β alone may well reflect the basal levels of arachidonic acid present in cells. Alternatively, IL-1β may be acting on both components, inducing COX-2 and partially activating PLA2 (Fig. 6). In addition, cytokines are able to induce cPLA2 and sPLA2 (Kol et al., 1997; Newton et al., 1997;Pruzanski et al., 1998) Thus, IL-1β in this study may also be up-regulating PLA2 enzymes. Nevertheless, in our experiments, we observed a strict synergism between IL-1β pretreatment and stimulation with either bradykinin, A23187, or arachidonic acid on PGE2 release from A549 cells.

    Figure 6
    View larger version:
    Figure 6

    Release of PGs by a two-component model. PG release is relatively low when cells are stimulated to either induce COX-2 (e.g., with IL-1β) (component 1) or activate PLA2 (e.g., with bradykinin) (component 2). However, PGs are released in relatively high proportions when both COX-2 is induced and PLA2 is activated. The two components are essentially related to amount of active COX-2 present and concentration of arachidonic acid available to it.

    Bradykinin is known to increase intracellular calcium in the A549 (Levesque et al., 1997) from a resting level to approximately 800 nM. In addition, A23187 has been shown to elicit similar increases in intracellular Ca++ in a number of in vitro systems (Vargaftig et al., 1980; Bradford et al., 1983). As such, bradykinin or A23187 will activate the cytosolic, intracellular form of PLA2, which requires an increase in calcium in the nanomolar range for activation and translocation to the nuclear and plasma (Glover et al., 1995, Schievella et al., 1995) membranes. Thus, bradykinin and A23187 are likely to be releasing PGE2 in our cells by activation of a calcium-dependent PLA2, either cPLA2 or sPLA2. Indeed, it should be noted that at high concentrations, A23187 may stimulate elevations in intracellular calcium that are sufficiently high to activate both cPLA2 and sPLA2. However, because theEmax for PGE2production by cells stimulated with bradykinin and A23187 were very similar, we may conclude that in each case, common levels of arachidonic acid were available to COX-2. Moreover, we found that the release of PGE2 stimulated either by bradykinin or A23187 from IL-1β-pretreated cells, was inhibited in a concentration-dependent fashion by the cPLA2inhibitor AACOCF3 (Bartoli et al., 1994; Riendeau et al., 1994). The observations are in keeping with others (Croxtall et al., 1996) showing that AACOCF3 inhibits arachidonic acid release by primed A549 cells. However, we also found that the release of PGE2 stimulated by arachidonic acid was similarly inhibited by AACOCF3. Experiments performed in the presence of exogenous arachidonic acid should remove in part the requirement for PLA2. It must be noted that arachidonic acid may also activate cells leading to liberation of substrate from intracellular stores. However, we found that AACOCF3 directly inhibited COX-2 in purified form at similar concentrations to those required for inhibition in whole cells. Thus, we show, for the first time, that AACOCF3 is a COX-2 inhibitor, an observation that renders this drug inaccurate as a tool to study the role of cPLA2 in prostanoid release in our system. In addition, the commercially available inhibitors of other forms of PLA2 (aristolochic acid, PACOCF3, or 12-epi-scalaradial) (Dennis, 1997) were relatively inactive as inhibitors of PGE2release by intact cells or formation by purified COX-2. Thus, we are not able to comprehensively address which PLA2(or indeed which lipase) is responsible for arachidonic acid release in our cells. However, it is clear that substrate liberation is an essential component of prostanoid release by cells expressing COX-2.

    Kinins such as bradykinin and kallidin act via two distinct receptor subtypes, B1 and B2. In this study, we show that the release of PGE2stimulated by bradykinin was inhibited by a B2antagonist. Moreover, the B1-selective agonist Des-Arg10-kallidin had no effect on prostanoid release. Thus, in A549 cells, bradykinin appears to be acting via its B2 receptors. Interestingly, recently, the expression of B2 receptors has been shown to increase in response to proinflammatory cytokines (Haddad et al., 1997). This, together with COX-2 induction, may help to explain why bradykinin is particularly active in and important for a variety of inflammatory responses.

    We found that bradykinin and A23187 elicit the release of similar levels of PGE2. Because A23187 acts independently of receptors, these observations suggest that either COX-2 or PLA2/arachidonic acid could be rate limiting. However, we found that cells stimulated with arachidonic acid released far greater levels of PGE2 than cells stimulated with either bradykinin or A23187. The way in which arachidonic acid stimulates the release of PGE2 from cells is not straightforward. For example, in addition to increasing substrate levels available to COX, arachidonic acid can stimulate cells (Damron et al., 1993). Indeed, we may expect that a portion of PGE2 formed by A549 cells stimulated with arachidonic acid originates from endogenous stores. Nevertheless, exogenous arachidonic acid was able to produce a much higher release of PGE2 than either bradykinin or A23187, suggesting that COX-2 is not the rate-limiting factor in prostanoid release, even when PLA2 is stimulated.

    The absence of detectable COX-1 (Mitchell et al., 1994) and the expression of COX-2 protein in A549 cells after IL-1β stimulation (Mitchell et al., 1994, 1997; this study) suggest that PGE2 production is mediated via COX-2. However, because COX-1 still may be present in small amounts and COX-1/COX-2 are located on distinct cellular membranes (Morita et al., 1995), it remains possible that bradykinin or A23187 can access different subcellular stores of arachidonic acid and hence preferentially supply one COX isoform. To further address this idea, we looked at the effect of the COX-2-selective inhibitor L-745,337 (Chan et al., 1995) and the mixed COX-1/COX-2 inhibitor indomethacin (Meade et al., 1993; Mitchell et al., 1993) on PGE2 release stimulated by bradykinin, A23187, or arachidonic acid. Chan et al. (1995)demonstrated that indomethacin was approximately equipotent as a inhibitor of COX-1 and COX-2, whereas L-745,337 had a similar potency as indomethacin against COX-2 but was 500-fold less potent against COX-1, with an IC50 value of >10 μM. As such, it is possible to use these two nonsteroidal anti-inflammatory agents to establish pharmacologically which COX isoform is responsible for the production of PGE2 from A549. Both indomethacin and L-745,337 inhibited the release of PGE2stimulated by bradykinin, A23187, or arachidonic acid with similar potencies, suggestive of COX-2 being responsible for the prostanoid formation. However, L-745,337 was slightly more potent as an inhibitor of PGE2 release stimulated by bradykinin than by either A23187 or arachidonic acid, which may support the idea of different pools of arachidonic acid being available to COX-2 (Reddy et al., 1996).

    Prostanoids are known to have a pivotal role in the inflammatory process. Indeed, the therapeutic benefits of nonsteroidal anti-inflammatory drugs are attributable to the inhibition of prostaglandin production (Vane, 1971). The “discovery” of a second isoform of COX, COX-2, has propagated research into the regulation of each isoform and their individual roles in overall prostanoid biosynthesis. Traditionally, it has been considered that prostanoid release was a one-component system. The only component required for COX-1-expressing cells was stimulation of PLA2 with agonists such as bradykinin, and for inflammatory cells, the component was induction of COX-2. The data presented here suggest that cells expressing the inflammatory isoform of COX-2, like those expressing COX-1, require a secondary stimulus to activate cPLA2 with subsequent release of prostanoids, thus establishing the requirement for a two-component system in prostanoid release at the site of inflammation. These observations may help to explain how the perpetuation of chronic inflammation occurs in diseases such as asthma and rheumatoid arthritis.

    Previous SectionNext Section

    Footnotes

    • Send reprint requests to: Dr. Jane A. Mitchell, Ph.D, Unit of Critical Care Medicine, Royal Brompton Hospital, Sydney Street, London SW3 6NP, United Kingdom. E-mail: j.mitchell{at}rbh.nthames.nhs.uk

    • ↵1 This work was supported by grants from the British Lung Foundation (to M.A.S.), Wellcome Trust (to B.M.G. and J.A.M.), British Heart Foundation (to T.D.W.), and Boehringer Ingelheim Pharma KG (to T.D.W.). Jane A. Mitchell is a Wellcome Career Development Fellow. A preliminary account of this work was presented at the British Pharmacological Society meeting (Saunders et al., 1996).

    • ↵2 Present address: Thoracic Medicine, Imperial College School of Medicine, National Heart and Lung Institute, Dovehouse Street, London, England SW3 6LY.

    • ↵3 Present address: Pharmacology Department, Rhone-Poulenc Rorer Research and Development, Dagenham Research Center, Rainham Road South, Dagenham, Essex, England RM10 7XS.

    • ↵4 Present address: Department of Pharmacology, University of Naples, Via Domenico Montesano, 49 80131 Napoli, Italy.

    • ↵5 Present address: Vascular Inflammation, The William Harvey Research Institute, Saint Bartholomew’s and the Royal London School of Medicine and Dentistry, Charterhouse Square, London, England EC1M 6BQ.

    • ↵6 Present address: Unit of Critical Care Medicine, Royal Brompton Hospital, Imperial College School of Medicine at the National Heart and Lung Institute, Sydney Street, London, England SW3 6NP.

    • Abbreviations:
      COX
      cyclooxygenase
      PLA2
      phospholipase A2
      PG
      prostaglandin
      IL-1β
      interleukin-1β
      AACOCF3
      arachidonate trifluoromethyl ketone
      PACOCF3
      palmitoyl trifluoromethyl ketone
      • Received April 23, 1998.
      • Accepted October 2, 1998.
    Previous Section
     

    References

    1. ↵
      1. Ackermann EJ,
      2. Conde-Frieboes K,
      3. Dennis EA
      (1995) Inhibition of macrophage calcium-independent phospholipase A2 by Bromeonol lactone and trifluoromethyl ketones. J Biol Chem 270:445–450.
      Abstract/FREE Full Text
    2. ↵
      1. Bartoli F,
      2. Lin HK,
      3. Ghomashchi F,
      4. Gelb MH,
      5. Jain MK,
      6. Apitz-Castro R
      (1994) Tight binding inhibitors of 85-kDa phospholipase A2 but not 14-kDa phospholipase A2 inhibit release of free arachidonate in thrombin-stimulated human platelets. J Biol Chem 269:15625–15630.
      Abstract/FREE Full Text
    3. ↵
      1. Belvisi MG,
      2. Saunders MA,
      3. Hirst SJ,
      4. Haddad EB,
      5. Yacoub MH,
      6. Mitchell JA
      (1997) Induction of cyclooxygenase by cytokines in cultured human airway smooth muscle cells: Novel inflammatory role of this cell type. Br J Pharmacol 120:910–916.
      CrossRefMedlineWeb of Science
    4. ↵
      1. Bradford PG,
      2. Marinetti GV,
      3. Abood LG
      (1983) Stimulation of phospholipase A2 and secretion of catecholamines from brain synaptosomes by potassium and A23187. J Neurochem 41:1684–1693.
      CrossRefMedlineWeb of Science
    5. ↵
      1. Burch RM,
      2. Axelrod J
      (1987) Dissociation of bradykinin induced prostaglandin formation from phosphatidylinositol turnover in Swiss 3T3 fibroblasts: Evidence for a G-protein regulation of phospholipase A2. Proc Natl Acad Sci USA 84:6374–6379.
      Abstract/FREE Full Text
    6. ↵
      1. Chan C-C,
      2. Boyce S,
      3. Brideau C,
      4. Ford-Hutchinson AW,
      5. Gordon R,
      6. Guay D,
      7. Hill RG,
      8. Li C-S,
      9. Mancini J,
      10. Penneton M,
      11. Prasit P,
      12. Rasori R,
      13. Riendeau D,
      14. Roy P,
      15. Tagari P,
      16. Vickers P,
      17. Wong E,
      18. Rodger IW
      (1995) Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: A novel non-steroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and non-human primate stomach. J Pharmacol Exp Ther 274:1531–1537.
      Abstract/FREE Full Text
    7. ↵
      1. Croxtall JD,
      2. Newman SP,
      3. Choudhury Q,
      4. Flower RJ
      (1996) The concerted regulation of cPLA2, COX-2 and lipocortin 1 expression by IL-1 beta in A549 cells. Biochem Biophys Res Commun 220:491–495.
      CrossRefMedlineWeb of Science
    8. ↵
      1. Damron DS,
      2. Van Wagoner DR,
      3. Moravec CS,
      4. Bond M
      (1993) Arachidonic acid and endothelin potentiate Ca2+ transients in rat cardiac myocytes via inhibition of distinct K+ channels. J Biol Chem 268:27335–27344.
      Abstract/FREE Full Text
    9. ↵
      1. Dennis EA
      (1997) The growing phospholipase A2 superfamily of signal transduction enzymes. Trends Biochem Sci 22:1–2.
      CrossRefMedlineWeb of Science
    10. ↵
      1. Giard DJ,
      2. Aaronson SA,
      3. Todaro GJ,
      4. Arnstein P,
      5. Kersey JH,
      6. Dosik P,
      7. Arks WP
      (1973) In vitro cultivation of human tumors: Establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 51:1417–1423.
    11. ↵
      1. Glover S,
      2. Batburt T,
      3. Jonas M,
      4. Chi E,
      5. Gelb MH
      (1995) Translocation of the 85-kDa phospholipase A2 from cytosol to the nuclear envelope in rat basophilic leukemia cells stimulated with calcium ionophore or IgE/antigen. J Biol Chem 270:15359–15367.
      Abstract/FREE Full Text
    12. ↵
      Haddad E-B, Fox AJ, Rousell J, Burgess GM, McIntyre P and Barnes PJ (1997) Cytokine up-regulation of bradykinin B1 and B2 receptor gene expression in human embryonic lung fibroblasts (Abstract).Am J Resp Crit Care Med A697..
    13. ↵
      1. Hamberg M,
      2. Svensson J,
      3. Samuelsson B
      (1974) Novel transformation of arachidonic acid in human platelets. Proc Natl Acad Sci USA 71:3400–3404.
      Abstract/FREE Full Text
    14. ↵
      1. Hempel S,
      2. Monick MM,
      3. Hunninghake GW
      (1994) Lipopolysaccharide induces prostaglandin H synthase-2 protein and mRNA in human alveolar macrophages and blood monocytes. J Clin Invest 93:391–396.
    15. ↵
      1. Hock FJ,
      2. Wirth K,
      3. Albus U,
      4. Linz W,
      5. Gerjards HJ,
      6. Wiemer G,
      7. Henke S,
      8. Breipohl G,
      9. Konig W,
      10. Knolle J
      (1991) Hoe 140, a new potent and long acting bradykinin-antagonist: In vitro studies. Br J Pharmacol 102:769–773.
      MedlineWeb of Science
    16. ↵
      1. Kol S,
      2. Ruutiainen-Altman K,
      3. Ben-Shlomo I,
      4. Payne DW,
      5. Ando M,
      6. Adashi EY
      (1997) The rat ovarian phospholipase A2 system: Gene expression, cellular localization, activity characterization, and interleukin-1 dependence. Endocrinology 138:322–331.
      Abstract/FREE Full Text
    17. ↵
      1. Lee SH,
      2. Soyoola E,
      3. Chanmugam P,
      4. Hart S,
      5. Sun W,
      6. Zhong H,
      7. Liou S,
      8. Simmons D,
      9. Hwang D
      (1992) Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem 267:25934–25938.
      Abstract/FREE Full Text
    18. ↵
      1. Levesque L,
      2. Dean NM,
      3. Sasmor H,
      4. Crooke ST
      (1997) Antisense oligonucleotides targeting human protein kinase C-α inhibit phorbol ester-induced reduction of bradykinin-evoked calcium mobilization in A549 cells. Mol Pharmacol 51:209–216.
      Abstract/FREE Full Text
    19. ↵
      1. Meade EA,
      2. Smith WL,
      3. DeWitt DL
      (1993) Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 268:6610–6614.
      Abstract/FREE Full Text
    20. ↵
      1. Mitchell JA,
      2. Akarasereenont P,
      3. Thiemermann C,
      4. Flower RJ,
      5. Vane JR
      (1993) Selectivity of non-steroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 90:11693–11697.
      Abstract/FREE Full Text
    21. ↵
      1. Mitchell JA,
      2. Belvisi MG,
      3. Akakresereenont P,
      4. Robbine RA,
      5. Kwon O-J,
      6. Croxtall J,
      7. Barnes PJ,
      8. Vane JR
      (1994) Induction of cyclooxygenase-2 by cytokines in human pulmonary epithelial cells: Regulation by dexamethasone. Br J Pharmacol 113:1008–1014.
      MedlineWeb of Science
    22. ↵
      1. Mitchell JA,
      2. Larkin S,
      3. Williams TJ
      (1995) Cyclooxygenase-2: Regulation and relevance in inflammation. Biochem Pharmacol 50:1535–1542.
      CrossRefMedlineWeb of Science
    23. ↵
      1. Mitchell JA,
      2. Saunders MA,
      3. Newton R,
      4. Barnes PJ,
      5. Belvisi MG
      (1997) Sodium salicylate inhibits COX-2 independently of nuclear factor kappa B: Role of arachidonic acid. Mol Pharmacol 51:907–912.
      Abstract/FREE Full Text
    24. ↵
      1. Morita I,
      2. Schindler M,
      3. Regier MK,
      4. Otto JC,
      5. Hori T,
      6. DeWitt DL,
      7. Smith WL
      (1995) Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J Biol Chem 270:10902–10908.
      Abstract/FREE Full Text
    25. ↵
      1. Mukherjee AB,
      2. Miele L,
      3. Pattabiraman N
      (1994) Phospholipase A2 enzymes: Regulation and physiological role. Biochem Pharmacol 48:1–10.
      CrossRefMedlineWeb of Science
    26. ↵
      1. Newton R,
      2. Kuitert LM,
      3. Slater DM,
      4. Adcock IM,
      5. Barnes PJ
      (1997) Cytokine induction of cytosolic phospholipase A2 and cyclooxygenase-2 mRNA is suppressed by glucocorticoids in human epithelial cells. Life Sci 60:67–78.
      CrossRefMedlineWeb of Science
    27. ↵
      1. Newman SP,
      2. Flower RJ,
      3. Croxtall JD
      (1994) Dexamethasone suppression of IL-1 beta-induced cyclooxygenase 2 expression is not mediated by lipocortin-1 in A549 cells. Biochem Biophys Res Commun 202:931–939.
      CrossRefMedlineWeb of Science
    28. ↵
      1. Pruzanski W,
      2. Stefanski E,
      3. Vadas P,
      4. Kennedy BP,
      5. van den Bosh H
      (1998) Regulation of the cellular expression of secretory and cytosolic phospholipase A2 and cyclooxygenase-2 by peptide growth factors. Biochemic Biophys Acta 1403:47–56.
      Medline
      1. Reddly ST,
      2. Hirschman HR
      (1996) Transcellular prostaglandin production following mast cell activation is mediated by proximal secretory phospholipase A2 and distal prostaglandin synthase 1. J Biol Chem 271:186–191.
      Abstract/FREE Full Text
    30. ↵
      1. Ricupero D,
      2. Taylor L,
      3. Polar P
      (1993) Interactions of bradykinin, calcium, G-protein and protein kinase in the activation of phospholipase A2 in bovine pulmonary artery endothelial cells. Agents Actions 40:110–118.
      CrossRefMedlineWeb of Science
    31. ↵
      1. Riendeau D,
      2. Guay J,
      3. Weech PK,
      4. Laliberte F,
      5. Li C,
      6. Desmarais S,
      7. Perrier H,
      8. Liu S,
      9. Nicoll-Griffith D
      (1994) Arachidonyl trifluoromethyl ketone, a potent inhibitor of 85-kDa phospholipase A2, blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets. J Biol Chem 269:15619–15624.
      Abstract/FREE Full Text
    32. ↵
      1. Saunders MA,
      2. Belvisi MG,
      3. Corden MB,
      4. Fox AJ,
      5. Evans TW,
      6. Barnes PJ,
      7. Mitchell JA
      (1996) Exacerbation of the release of prostaglandin E2 by bradykinin after COX-2 induction in human airway epithelial cells. Br J Pharmacol 119:46P.
    33. ↵
      1. Schievella AR,
      2. Regier MK,
      3. Smith WL,
      4. Lin LL
      (1995) Calcium-mediated translocation of cytosolic phospholipase A2 to the nuclear envelope and endoplasmic reticulum. J Biol Chem 51:30749–30754.
    34. ↵
      1. Slivka SR,
      2. Insel PA
      (1988) Phorbol ester and neomycin dissociate bradykinin receptor-mediated arachidonic acid release and polyphosphoinositide hydrolysis in Madin-Darby canine kidney cells: Evidence that bradykinin mediates non-interdependent activation of phospholipases A2 and C. J Biol Chem 263:14640–14647.
      Abstract/FREE Full Text
    35. ↵
      1. Vadas P,
      2. Stefanski E,
      3. Wloch M,
      4. Grouix B,
      5. Van Den Bosch H,
      6. Kennedy B
      (1996) Secretory non-pancreatic phospholipase A2 and cyclooxygenase-2 expression by tracheobronchial smooth muscle cells. Eur J Biochem 235:557–563.
      MedlineWeb of Science
    36. ↵
      1. Vane JR
      (1971) Inhibition of prostaglandin synthesis as a mechansim of action for aspirin-like drugs. Nat New Biol 231:232–235.
      MedlineWeb of Science
    37. ↵
      1. Vane JR,
      2. Mitchell JA,
      3. Appleton I,
      4. Tomlinson A,
      5. Bishop-Bailey DA,
      6. Croxtall J,
      7. Willoughby D
      (1994) Inducible isoforms of cyclooxygenase and nitric oxide synthase in inflammation. Proc Natl Acad Sci USA 91:2046–2050.
      Abstract/FREE Full Text
    38. ↵
      1. Vargaftig BB,
      2. Fouque F,
      3. Chignard M
      (1980) Interference of bromophenacyl bromide with platelet phospholipase A2 activity induced by thrombin and by the ionophore A23187. Thromb Res 17:91–102.
      CrossRefMedline
    39. ↵
      1. Xie WL,
      2. Chipman JG,
      3. Robetson DL,
      4. Erikson RL,
      5. Simmons DL
      (1991) Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 88:2692–2696.
      Abstract/FREE Full Text
    « Previous | Next Article »Table of Contents

    This Article

    1. JPET March 1, 1999 vol. 288 no. 3 1101-1106
    1. AbstractFree
    2. » Full Text
    3. Full Text (PDF)

    Classifications

    Responses

    1. Submit a response
    2. No responses published

    Navigate This Article

    Current Issue

    1. November 2009, 331 (2)
    1. Current Issue
    1. Alert me to new issues of JPET